Pros on CNBC discussed Biogen after the Food and Drug Administration approved its Alzheimer's drug.
Market Movers rounded up the best reactions from investors and analysts on Biogen . The experts discussed the biotech company after the Food and Drug Administration approved its Alzheimer's treatment Leqembi , paving the way for broader Medicare coverage.
The drug slowed cognitive decline in trials, but poses risks of brain swelling and bleeding and comes with a $26,500 per year price tag. Biogen collaborated with Japanese pharmaceutical company Eisai to make Leqembi. Despite the approval, Biogen shares slid more than 3% by Friday's market close and are down nearly 10% over the past month.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
US FDA grants standard approval of Eisai/Biogen Alzheimer's drugA new milestone for a fatal disease that has eluded drugmakers' efforts for decades.
Leer más »
Biogen’s stock slides premarket as analysts take mixed view of Alzheimer’s disease drug approvalBiogen Inc.’s stock rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval...
Leer más »
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and moreThese are the stocks posting the largest moves in midday trading.
Leer más »
Should Runners Be Eating a High-Protein Diet?We explain the pros and cons of beefing up intake of this macronutrient.
Leer más »
Biogen’s big Alzheimer’s drug win fails to boost the stock as analysts see slow Leqembi rolloutMilestone Leqembi approval is “a mixed bag,” analysts say, given drug label's risk warnings and infusion-center bottlenecks.
Leer más »
The first drug that slows Alzheimer's has finally received FDA approval | EngadgetJapanese drugmaker Eisai and US-based Biogen have received FDA approval for Leqembi, making it the first approved treatment available that can slow the progression of Alzheimer’s in patients..
Leer más »